Key result
Direct thrombin inhibitors offer a targeted alternative to classic anticoagulants like heparin and vitamin K antagonists for the medical intervention of pathologic thrombosis.
This review summarizes the nature, current indications, and ongoing trials of direct thrombin inhibitors as an alternative to traditional anticoagulants.
Cardiovascular disease is a leading cause of death and pathologic coagulation plays an integral role in the development, propagation, and intervention of cardiovascular disease. The 2 classic anticoagulants, heparin and vitamin K antagonists, though having served humanity for nearly a century, are both inconvenient and nonspecific. Through both direct and indirect roles, thrombin is essential to coagulation, and makes for a very attractive target in medical intervention of pathologic thrombosis. This article will review the nature of direct thrombin inhibitors, current indications, and ongoing trials.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2011) conducted a review in Cardiovascular disease. Direct thrombin inhibitors was evaluated. Direct thrombin inhibitors offer a targeted alternative to classic anticoagulants like heparin and vitamin K antagonists for the medical intervention of pathologic thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: